alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 20.106 Studies and reports prepared by or with funds provided by the Food and Drug Administration. ( a ) The following types of reports and studies prepared by or with funds provided by the Food and Drug Administration are available for public disclosure upon their acceptance by the responsible agency official: ( 1 ) Quarterly and annual reports of the agency.
( 2 ) External investigations or review of agency needs and performance.
( 3 ) Surveys, compilations, and summaries of data and information.
( 4 ) Consumer surveys.
( 5 ) Compliance surveys.
( 6 ) Compliance programs, except that names of specific firms, the location of specific activities, and details about sampling numbers or sizes shall be deleted until implementation of the program is completed.
( 7 ) Work plans prepared by Food and Drug Administration centers, field offices, and other components, except that names of specific firms, the location of specific activities, and details about sampling numbers or sizes shall be deleted until implementation of the plan is completed.
( b ) The following types of reports and studies prepared by or with funds provided by the Food and Drug Administration are not available for public disclosure: ( 1 ) Internal audits of agency needs and performance.
( 2 ) Records relating to the internal planning and budget process.
( 3 ) Legislative proposals or comments prior to submission to Congress.
[42 FR 15616, Mar. 22, 1977, as amended at 50 FR 8995, Mar. 6, 1985]
#### § 211.176 Penicillin contamination.

If a reasonable possibility exists that a non-penicillin drug product has been exposed to cross-contamination with penicillin, the non-penicillin drug product shall be tested for the presence of penicillin. Such drug product shall not be marketed if detectable levels are found when tested according to procedures specified in ‘Procedures for Detecting and Measuring Penicillin Contamination in Drugs,’ which is incorporated by reference. Copies are available from the Division of Research and Testing (HFD-470), Center for Drug Evaluation and Research, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html.*

[43 FR 45077, Sept. 29, 1978, as amended at 47 FR 9396, Mar. 5, 1982; 50 FR 8996, Mar. 6, 1985; 55 FR 11577, Mar. 29, 1990; 66 FR 56035, Nov. 6, 2001; 69 FR 18803, Apr. 9, 2004; 81 FR 49897, July 29, 2016]
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                         136,295
<SECURITIES>                                         0
<RECEIVABLES>                                  510,664
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                      34,142,244
<DEPRECIATION>                            (18,835,569)
<TOTAL-ASSETS>                              30,089,044
<CURRENT-LIABILITIES>                        1,751,284
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                (10,994,587)
<TOTAL-LIABILITY-AND-EQUITY>                30,089,044
<SALES>                                     13,580,561
<TOTAL-REVENUES>                            13,580,561
<CGS>                                                0
<TOTAL-COSTS>                                8,029,263
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           2,504,989
<INCOME-PRETAX>                              (498,107)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (498,107)
<EPS-BASIC>                                        0
<EPS-DILUTED>                                        0


</TABLE>
IV 

115TH CONGRESS 

1ST SESSION H. RES. 650 

Recognizing the results of the free and fair elections for the new Members 

of the Legislative Assembly of the Falkland Islands held on November 

9, 2017. 

IN THE HOUSE OF REPRESENTATIVES 

DECEMBER 7, 2017 

Mr. DIAZ-BALART (for himself, Mr. HOLDING, and Mr. KILMER) submitted 

the following resolution; which was referred to the Committee on Foreign 

Affairs 

RESOLUTION 

Recognizing the results of the free and fair elections for 

the new Members of the Legislative Assembly of the 

Falkland Islands held on November 9, 2017. 

Whereas the United States supports the principles of democratic processes across the world; 

Whereas the Falkland Islands referendum of March 2013 

clearly set out the wishes of the Islanders, when 99.8 percent of those who voted chose to maintain their status as 

an Overseas Territory of the United Kingdom; 

Whereas the people of the Falkland Islands have the right to 

decide their own future as enshrined in the United Nations Charter and in Article One of the two United Nations Covenants on Human Rights, by which they freely 


lotter on DSKBCFDHB2PROD with BILLS
2 

•HRES 650 IH 

determine their political status and pursue their economic, social, and cultural development free from intimidation and harassment; 

Whereas it is the obligation of countries to respect the legally 

binding principle of self-determination; 

Whereas the Falkland Islands’ election on November 9, 2017, 

is an expression of that principle of self-determination; 

and 

Whereas the United Kingdom is a loyal ally that has stood 

by the United States for over a century: Now, therefore, 

be it 

1 Resolved, That the House of Representatives— 

2 (1) welcomes the free, fair, and democratic elec3 tions of the Falkland Islands; 

4 (2) acknowledges that only the people of the 

5 Falkland Islands can determine the future of the 

6 Falkland Islands; and 

7 (3) recognizes the United Kingdom’s sov8 ereignty over the Falkland Islands for as long as the 

9 Islands desire to remain a self-governing Overseas 

10 Territory. 

Æ 


lotter on DSKBCFDHB2PROD with BILLS
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1250 Cellulase enzyme preparation derived from Trichoderma longibrachiatum. ( a ) Cellulase enzyme preparation is derived from a nonpathogenic, nontoxicogenic strain of *Trichoderma longibrachiatum* (formerly *T. reesei*). The enzyme, cellulase, catalyzes the endohydrolysis of 1,4-beta-glycosidic linkages in cellulose. It is obtained from the culture filtrate resulting from a pure culture fermentation process.
( b ) The ingredient meets the general and additional requirements for enzyme preparations in the monograph specifications on enzyme preparations in the “Food Chemicals Codex,” 4th ed. (1996), pp. 129 to 134, which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Box 285, Washington, DC 20055 (Internet *http://www.nap.edu*), or may be examined at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used in food as an enzyme as defined in § 170.3(o)(9) of this chapter for the breakdown of cellulose.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice.
[64 FR 28361, May 26, 1999, as amended at 81 FR 5595, Feb. 3, 2016; 88 FR 17724, Mar. 24, 2023]
[No. 38939-4-I.

Division One.

December 8, 1997.]

#### The State of Washington, *Respondent,*v. Richard Alan Dyson, *Appellant.*

Appeal from a judgment of the Superior Court for King County, No. 96-1-01613-2, Donald D. Haley, J., entered July 1, 1996. *Reversed*by unpublished per curiam opinion. Now published at 90 Wn. App. 433.
§ 209.1 Scope and purpose. ( a ) This part sets forth requirements for human prescription drug products approved under section 505 of the Federal Food, Drug, and Cosmetic Act and dispensed by authorized dispensers and pharmacies to consumers. This part requires distribution of a side effects statement and applies to new and refill prescriptions. This part is not intended to apply to authorized dispensers dispensing or administering prescription drug products to inpatients in a hospital or health care facility under an order of a licensed practitioner, or as part of supervised home health care.
( b ) The purpose of providing the side effects statement is to enable consumers to report side effects of prescription drug products to FDA.
H. Res. 989

In the House of Representatives, U. S., 

September 26, 2006.

Whereas on August 10, 2006, British police arrested 24 people for plotting to commit acts of terror on trans-Atlantic 

flights; 

Whereas as of August 31, 2006, 12 citizens have been 

charged for their roles in the terror plot, including eight 

citizens charged with conspiracy to murder; 

Whereas United Kingdom authorities acted swiftly and decisively to prevent a horrific attack on scores of innocent 

people; 

Whereas the United Kingdom and the United States have 

been close allies in not only two World Wars and Operation Desert Storm, but also the Global War on Terror; 

Whereas the intelligence and military communities of the 

United Kingdom and the United States continue to work 

together to win the Global War on Terror; 

Whereas the threat of terrorism is a grave concern for all nations, regardless of geographical or other boundaries; 

Whereas acts of terror have profoundly affected citizens 

across the globe, including those in Egypt, India, Indonesia, Jordan, Spain, Turkey, the United Kingdom, and 

the United States; and 
2

•HRES 989 EH 

Whereas victory in the Global War on Terror is a necessity 

to ensure the liberty and safety of all people: Now, therefore, be it 

Resolved, That the House of Representatives—

(1) commends the law enforcement authorities of 

the United Kingdom on their action to prevent a terrible 

attack from occurring; 

(2) commends the intelligence community of the 

United Kingdom for its outstanding work in identifying 

the citizens seeking to carry out this plot; 

(3) condemns those that would use acts of violence 

against innocent civilians to spread a message of hate 

and intolerance; and 

(4) urges the allies of the United States in the 

Global War on Terror to remain steadfast in the execution of this important mission. 

Attest:

Clerk.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>                     <C>
<PERIOD-TYPE>                   YEAR                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998             DEC-31-1999
<PERIOD-START>                             JAN-01-1998             JAN-01-1999
<PERIOD-END>                               DEC-31-1998             MAR-31-1999
<CASH>                                           6,818                   7,931
<SECURITIES>                                    12,650                  12,676
<RECEIVABLES>                                        0                       0
<ALLOWANCES>                                         0                       0
<INVENTORY>                                          0                       0
<CURRENT-ASSETS>                                19,940                  21,049
<PP&E>                                           1,258                   1,423
<DEPRECIATION>                                       0                       0
<TOTAL-ASSETS>                                  21,472                  22,693
<CURRENT-LIABILITIES>                            2,074                   1,731
<BONDS>                                              0                      66
<PREFERRED-MANDATORY>                                0                       0
<PREFERRED>                                          0                       0
<COMMON>                                            71                      77
<OTHER-SE>                                      33,662                  38,914
<TOTAL-LIABILITY-AND-EQUITY>                    21,472                  22,693
<SALES>                                              0                       0
<TOTAL-REVENUES>                                     0                       0
<CGS>                                                0                       0
<TOTAL-COSTS>                                        0                       0
<OTHER-EXPENSES>                                10,176                   4,044
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                                   0                       1
<INCOME-PRETAX>                                (9,163)                 (3,760)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                                  0                       0
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                   (9,163)                 (3,760)
<EPS-PRIMARY>                                   (1.48)                   (.49)
<EPS-DILUTED>                                   (1.48)                   (.49)
        

</TABLE>
§ 347.12 Astringent active ingredients. The active ingredient of the product consists of any one of the following within the specified concentration established for each ingredient: ( a ) Aluminum acetate, 0.13 to 0.5 percent (depending on the formulation and concentration of the marketed product, the manufacturer must provide adequate directions so that the resulting solution to be used by the consumer contains 0.13 to 0.5 percent aluminum acetate).
( b ) Aluminum sulfate, 46 to 63 percent (the concentration is based on the anhydrous equivalent).
( c ) Witch hazel.
316B PHASE III RULE

TELEPHONE LOG

Name of Caller: John Sunda, SAIC

Date: February 12, 2009

Company Name: Blue Stream Services

Street Address:

City/State/ZIP: New Iberia, LA

Person Contacted: Richard Brister

Title: Cooling Tower Specialist

Telephone #: 504-400-0093

E-Mail: rabrister@bellsouth.net 

 

Called to inquire about modular tower design and why power use was higher

He said the 3000 ton units use more fan power because of their compact design. This design 

allows for more flow and cooling capacity per unit that other designs and especially compared to 

large permanent towers. Not only does this save on space but also costs since each unit will have 

costs such as shipping, installation, rental, etc that are more sensitive to the number of units than 

the unit size. Thus, more cooling per unit equals less costs. Typically, each unit uses 400 amps 

and if single unit pumps are used they require 400 amps as well. 

I asked about approach values and he said a typical design spec for the 3000 ton unit would be:

Hot water: 95oF

Cold Water: 85oF
Wet Bulb: 78o

F

Thus, in this instance the approach would be 7oF and in general, the approach will range between 

7 and 10oF. Of course this would vary with flow, range, wet bulb temperature, and type of fill 

used.

They use a Brentwood film type fill and that the fill selected will be determined by the quality of 

the water. Typical fill might be the Brentwood CF1900 Cross Fluted Film Fill Media. This is 

rated on the Brentwood website as suitable for “average to good” water which is defined as:

Use CF-1200 or CF-1900 when:

• TSS < 25 PPM (<100 PPM where bacterial activity is very low)

• Make-up from uncontaminated sources

• Good biological & scale control

• Low cycles of concentration

• Minimal airborne dust

• No oils or grease

If the water quality is poor and contains solids that might tend to clog fill then a fill with larger 

openings is selected. Such fill will be less efficient (less surface area and less air water contact) 

and may reduce efficiency by 6 to 10%. If all else is equal this will increase the approach.

I asked whether he knew of any situations where a cooling tower produced cooler water than the 

surface source water. He said they were working on one project (deal not yet sealed) in Texas 

where the lake water reaches 95oF in the summer. Operating in a helper tower mode, they figure 

that they will be able to return cooling water back to the lake at a temperature lower than 95 oF 

and thus actually reduce the lake temperature. He noted that one of their selling points is that they

actually increase DO in the discharge whereas once-through tends to do the opposite. I suggested 

they look at using a recirculating mode. He said they usually use a design wet bulb temperature 

of around 78 oF but that it might be higher in areas along the Gulf like in Louisiana where it 

might be 80-81 oF. Even then, these design wet bulb values are present only a fraction of the 

time.
#### § 290.6 Spanish-language version of required warning.

By direction of section 305(c) of the Federal Controlled Substances Act, § 290.5, promulgated under section 503(b) of the Federal Food, Drug, and Cosmetic Act, requires the following warning on the label of certain drugs when dispensed to or for a patient: “Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed.” The Spanish version of this is: “Precaucion: La ley Federal prohibe el transferir de esta droga a otra persona que no sea el paciente para quien fue recetada.”
DATE: December 27, 2011

TO: The Record -- Docket # EPA-HQ-RCRA-2008-0808

FROM: Elaine Eby, Environmental Scientist, MRWMD, ORCR, EPA

SUBJECT: Conversations with American Petroleum Institute and Gasification Technology 

Council Regarding Use of the Petroleum Exclusion found at 40 CFR 

261.4(a)(12)(i).

On Tuesday, October 25, 2011, I contacted Derek D. Swick of the American Petroleum Institute 

and Robert Childress of the Gasification Technology Council. The purpose of this 

communication was to inquire as to whether they were aware of any petroleum refinery 

currently using the gasification exclusion for oil-bearing hazardous secondary materials found at 

40 CFR 261.4(a) (12)(i). Mr. Swick answered that, in canvassing his members, he was unaware 

of anyone claiming to be using the exclusion. Mr. Childress referred me to Rob Childress, also of 

the Gasification Technology Council, who after some checking, responded that he was unaware 

of any petroleum refinery currently using the exclusion.
§ 211.134 Drug product inspection. ( a ) Packaged and labeled products shall be examined during finishing operations to provide assurance that containers and packages in the lot have the correct label.
( b ) A representative sample of units shall be collected at the completion of finishing operations and shall be visually examined for correct labeling.
( c ) Results of these examinations shall be recorded in the batch production or control records.
§ 26.68 Withdrawal of listed conformity assessment bodies. The following procedures shall apply with regard to the withdrawal from subpart B of this part of a conformity assessment body (CAB): ( a ) A party proposing to withdraw a CAB listed in subpart B of this part shall forward its proposal in writing to the other party;
( b ) Such CAB shall be promptly notified by the other party and shall be provided a period of at least 30 days from receipt to provide information in order to refute or to correct the deficiencies which form the basis of the proposed withdrawal;
( c ) Within 60 days following receipt of the proposal, the other party shall indicate its position regarding either its confirmation or its opposition. Upon confirmation, the withdrawal from the list in subpart B of this part of the CAB shall take effect;
( d ) In the event the other party opposes the proposal to withdraw by supporting the technical competence and compliance of the CAB, the CAB shall not at that time be withdrawn from the list of CAB's in subpart B of this part. In this instance, the Joint Sectoral Committee or the Joint Committee may decide to carry out a joint verification of the body concerned. After the completion of such verification, the proposal for withdrawal of the CAB may be resubmitted to the other party; and
( e ) Subsequent to the withdrawal of a CAB listed in subpart B of this part, a party shall continue to accept the results of conformity assessment procedures performed by that CAB prior to withdrawal, unless a regulatory authority of the party decides otherwise based on health, safety, and environmental considerations or failure to satisfy other requirements within the scope of subpart B of this part.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Commodity Futures Trading Commission

# TIME AND DATE:

11 a.m., Friday, January 14, 2011.

# PLACE:

1155 21st St., NW., Washington, DC, 9th Floor Commission Conference Room.

# STATUS:

Closed.

# MATTERS TO BE CONSIDERED:

Surveillance and Enforcement Matters.

# CONTACT PERSON FOR MORE INFORMATION:

Sauntia S. Warfield, 202-418-5084.

Sauntia S. Warfield,

Assistant Secretary of the Commission.

[FR Doc. 2010-32781 Filed 12-23-10; 4:15 pm]

BILLING CODE 6351-01-P